The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
[5-(2,4-Difluoro-phenyl)-thiophen-2-yl]-(2,4,5-trifluoro-3-hydroxy-phenyl)-methanone ID: ALA4092593
PubChem CID: 122652926
Max Phase: Preclinical
Molecular Formula: C17H7F5O2S
Molecular Weight: 370.30
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(c1ccc(-c2ccc(F)cc2F)s1)c1cc(F)c(F)c(O)c1F
Standard InChI: InChI=1S/C17H7F5O2S/c18-7-1-2-8(10(19)5-7)12-3-4-13(25-12)16(23)9-6-11(20)15(22)17(24)14(9)21/h1-6,24H
Standard InChI Key: QVHCDCUIBFYPSB-UHFFFAOYSA-N
Molfile:
RDKit 2D
25 27 0 0 0 0 0 0 0 0999 V2000
14.5278 -10.6937 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.3450 -10.6937 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
15.5994 -9.9170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.9364 -9.4348 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2777 -9.9170 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.3732 -9.6641 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9796 -10.2135 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.7565 -9.9626 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.9282 -9.1628 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.3167 -8.6143 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.5422 -8.8680 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.8078 -11.0124 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
18.7054 -8.9103 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
14.0466 -11.3542 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.2340 -11.2677 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
14.3780 -12.1012 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.8951 -12.7615 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.2258 -13.5079 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.0393 -13.5949 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.5208 -12.9295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.1874 -12.1857 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.0825 -12.6741 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
13.7443 -14.1682 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
15.3717 -14.3415 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
16.3337 -13.0131 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 1 0
3 4 2 0
4 5 1 0
5 1 2 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
3 6 1 0
7 12 1 0
9 13 1 0
1 14 1 0
14 15 2 0
14 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 16 1 0
17 22 1 0
18 23 1 0
19 24 1 0
20 25 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 370.30Molecular Weight (Monoisotopic): 370.0087AlogP: 5.05#Rotatable Bonds: 3Polar Surface Area: 37.30Molecular Species: ACIDHBA: 3HBD: 1#RO5 Violations: 1HBA (Lipinski): 2HBD (Lipinski): 1#RO5 Violations (Lipinski): 1CX Acidic pKa: 6.18CX Basic pKa: ┄CX LogP: 5.40CX LogD: 4.23Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.40Np Likeness Score: -0.89
References 1. Abdelsamie AS, van Koppen CJ, Bey E, Salah M, Börger C, Siebenbürger L, Laschke MW, Menger MD, Frotscher M.. (2017) Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study., 127 [PMID:27852458 ] [10.1016/j.ejmech.2016.11.004 ] 2. Siebenbuerger L, Hernandez-Olmos V, Abdelsamie AS, Frotscher M, van Koppen CJ, Marchais-Oberwinkler S, Scheuer C, Laschke MW, Menger MD, Boerger C, Hartmann RW.. (2018) Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy., 61 (23): [PMID:30480443 ] [10.1021/acs.jmedchem.8b01373 ]